SciELO - Scientific Electronic Library Online

 
vol.129 issue5Hand dysfunction in scleroderma patientsAntifibrinolytic drugs for acute traumatic injury author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Sao Paulo Medical Journal

Print version ISSN 1516-3180

Sao Paulo Med. J. vol.129 no.5 São Paulo  2011

http://dx.doi.org/10.1590/S1516-31802011000500013 

LETTER TO THE EDITOR

 

Confidential unit exclusion and blood safety

 

Exclusão confidencial da unidade e segurança do sangue

 

 

Seyed Moayed Alavian

MD, PhD. Professor of Gastroenterology and Hepatology, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, Iran

Address for correspondence

 

 

Dear Editor,

I read with interest the article by Kasraian et al., recently published in your journal.1 They concluded that because of the higher prevalence of HBS, HCV and HIV positivity among blood donors who chose the confidential unit exclusion (CUE) option, offering CUE to blood donors could be a potentially useful method for improving blood safety, since it could increase the detection of infected blood during the window period.

I would like to open the issue for further discussion. Iran is an area of low endemicity for HCV infection, and the most common risk factors are histories of blood transfusion and intravenous addiction.2,3 However, for HBV infection, the most common risk factor is transmission during childhood, and most HBV-infected patients are unaware of their infection.4 Donor selection is an important strategy for blood safety, but it is not enough! CUE, in which the physician asks the donor whether he or she wants his/her blood to be used for transfusion or not, has been added in order to obtain safer blood and blood products. The donor is asked to choose "Use my blood" if he/she has given truthful answers to the questions and, if the questions have not been answered truthfully, is asked to choose "Do not use my blood". Although applying additional policies to maintain safety may lead to more donor rejection and to the exclusion of more blood for transfusion, these policies may vary for each region. Donor screening through physician assessment is still one of the most important components contributing towards providing healthy blood and blood products. The effectiveness of this CUE policy has been unclear. In a study performed by Kean et al. in the United States, 50% of the donors who chose "Do not use my blood" had made this choice mistakenly or due to lack of knowledge about this choice.5

Finally, I think that the effectiveness of confidential self-exclusion (CSE) systems depends on the risk factors for transfusion-transmitted infections and the educational level of blood donors in each country.

 

REFERENCES

1. Kasraian L, Tavasoli A. Positivity of HIV, hepatitis B and hepatitis C in patients enrolled in a confidential self-exclusion system of blood donation: a cross-sectional analytical study. Sao Paulo Med J. 2010;128(6):320-3.         [ Links ]

2. Alavian SM, Ahmadzad-Asl M, Lankarani KB, et al. Hepatitis C infection in the general population of Iran: a systematic review. Hepatitis Monthly. 2009;9(3):211-23. Available from: http://hepatmon.com/pdf/Hepatitis_C_Infection_in_the_General_Pop.pdf. Accessed in 2010 (Mar 31).         [ Links ]

3. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002;17(10):1092-7.         [ Links ]

4. Nokhodian Z, Kassaian N, Ataei B, et al. Hepatitis B markers in Isfahan, Central Iran: a population-based study. Hepatitis Monthly. 2009;9(1):12-6. Available from: http://hepatmon.com/pdf/Hepatitis_B_Markers_in_Isfahan_Central_I.pdf. Accessed in 2010 (Mar 31).         [ Links ]

5. Kean CA, Hsueh Y, Querin JJ, Keating LJ, Allensworth DD. A study of confidential unit exclusion. Transfusion. 1990;30(8):707-9.         [ Links ]

 

 

Address for correspondence:
Seyed Moayed Alavian, MD
Professor of Gastroenterology and Hepatology, Director of Baqiyatallah Research Center for Gastroenterology and Liver Disease
Tel/Fax: +98 21 88945186-8, +98 21 81262072
Postal Address: P.O. Box 14155/3651
Tehran, Iran
E mail: alavian@thc.ir

Date of first submission: March 3, 2011
Last received: March 3, 2011
Accepted: April 12, 2011
Sources of funding: None
Conflict of interest: None

 

 

Baqiyatallah Research Center for Gastroneterology and Liver Diseases, Tehran, Iran